home / stock / nrx:cc / nrx:cc news

NRX:CC News and Press, NurExone Biologic Inc.

Stock Information
Company Name: NurExone Biologic Inc.
Stock Symbol: NRX:CC
Market: TSXVC
Website: nurexone.com
Menu
Get NRX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
NRX:CC - Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce tod...
NRX:CC - NurExone Biologic GAAP EPS of -$0.03

2026-06-05 11:28:32 ET More on NurExone Biologic NurExone Biologic reports FY results Historical earnings data for NurExone Biologic Financial information for NurExone Biologic Read the full article on Seeking Alpha For further details see: NurExo...

NRX:CC - NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its fin...

NRX:CC - Expected Canadian Company Earnings on Tuesday, May 26th, 2026

Luca Mining Corp. (LUCA:CA) is expected to report $-0.01 for Q1 2026 NurExone Biologic Inc. (NRX:CA) is expected to report $-0.03 for Q1 2026 Organto Foods Inc. (OGO:CA) is expected to report $0 for Q1 2026 Tribe Property Technologies Inc. (TRBE:CA) is expected to report $-0.02 for Q1...
NRX:CC - NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean...

NRX:CC - NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injur...

NRX:CC - Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, is pleased to ann...
NRX:CC - 5 Best-performing Canadian Pharma Stocks in 2026

2026-04-21 16:15:00 ET From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic. Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies su...

NRX:CC - NurExone Biologic reports FY results

2026-04-17 09:01:26 ET More on NurExone Biologic Historical earnings data for NurExone Biologic Financial information for NurExone Biologic Read the full article on Seeking Alpha For further details see: NurExone Biologic reports FY results

NRX:CC - NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system (“ CNS ”) inj...
Next 10